Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Delivers more cancer-killing SN-38 molecules to tumor than irinotecan and Onivyde®
Studies support potential benefit as an improved treatment with fewer side effects
HANOVER, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) announces positive data from preclinical studies that support the potential for NGC-Iri to have improved efficacy and a better side effect profile compared with the commonly used FDA-approved cancer treatments irinotecan and Onivyde® (the liposomal formulation of irinotecan). Next Generation irinotecan (NGC-Iri) is a prodrug of SN-38, which is the active anticancer metabolite of irinotecan.
In two studies with the human melanoma xenograft mouse model, the accumulation of SN-38 in the tumor plasma and other tissues following treatment with NGC-Iri and Onivyde® were compared with the accumulation following treatment with irinotecan. One study compared NGC-Iri with irinotecan, and the other compared Onivyde® with irinotecan. The two studies demonstrated that in mice that were administered the same amount of SN-38:
Posted In: PCSA